Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin briefly tops $83,000 as tech stocks rebound, but falls back amid resistance near $84,000.

Market News
19 Oct 2026
Coindesk
View Source
Neutral
Bitcoin briefly tops $83,000 as tech stocks rebound, but falls back amid resistance near $84,000.

Bitcoin rose from around $80,700 overnight to briefly surpass $83,000 early Monday before slipping back to about $82,400. This move coincided with a rebound in tech stocks, including a 1.1% gain in Nasdaq 100 futures and a 3% jump in a chipmaker ETF. Despite the bounce, Bitcoin remains about $1,000 below a resistance level near $84,000 that capped gains last week. Investors are watching if a break above $84,000 could signal a stronger tech-driven rally for Bitcoin. Meanwhile, European markets weakened due to protests in France and bond selloffs, with the euro underperforming major currencies.

Bitcoin's recent price action includes a brief rise above $83,000 before slipping back to about $82,400. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 17:02 WIB: out of 50 major cryptocurrencies, 33 rose and 16 fell today. Notable movers include BAL (Balancer) with a 1-day change of +11.14% at Rp16.297, EOS (EOS.IO) up 8.13% at Rp12.649, and SAND (The Sandbox) down 5.15% at Rp1.055 with a Pluang order activity of 35% Sell / 65% Buy and a typical hold time of 123 days.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
24 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
24 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
24 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
24 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
24 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App